Israel
MeMed is a leading med tech and bio-convergence company, pioneering innovative diagnostic host immune response testing methods in the Biotechnology and Health Care sectors. The company's slogan "Decoding the Host Immune Response to Generate Insights that Improve Lives" reflects its commitment to developing solutions that address complex clinical dilemmas and improve patient outcomes.
Founded in 2009 and headquartered in Israel, MeMed is at the forefront of translating the complex signals of the immune system into simple diagnostic insights that transform the way infectious diseases and inflammatory disorders are treated.
The company received a significant $93.00M Venture Round investment on 10 January 2022, demonstrating strong investor confidence in its innovative approach. Notable investors in this round include Social Capital, Horizons Ventures, Western Technology Investment, Lamaison Partners, Paolim Capital Markets, Shavit Capital, Touchwood Capital, Union Tech Ventures, Phoenix Insurance, and Caesarea Medical Electronics.
MeMed's focus on leveraging immune system insights to improve diagnostic capabilities and treatment outcomes positions the company as a strong contender in the burgeoning field of med tech and bio-convergence. With the recent substantial investment, MeMed is well-positioned for further growth and impact in the healthcare industry.
